(S,Z)-5-Amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one

We are (S,Z)-5-Amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one CAS:156732-13-7 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:(S,Z)-5-Amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one
CAS.NO:156732-13-7
Synonyms:(S,Z)-5-Amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one
5S-2-Amino-5-dibenzylamino-4-oxo-1,6-diphenylhex-2-ene
(2S,4Z)-5-Amino-2-[bis(phenylmethyl)amino]-1,6-diphenyl-4-hexen-3-one
(2S,4Z)-5-Amino-2-(dibenzylamino)-1,6-diphenyl-4-hexen-3-one
5S-2-Amino-5-dibenzylamino-4-oxo-1,6-diphenylhex-2-ene
 
Physical and Chemical Properties:
Density 1.1±0.1 g/cm3
Boiling Point 626.2±55.0 °C at 760 mmHg
Molecular Formula C32H32N2O
Molecular Weight 460.609
Flash Point 332.5±31.5 °C
 
Specification:
Appearance:White to light yellow powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:Intermediate of Ritonavir(CAS:155213-67-5).

(S,Z)-5-Amino-2-(dibenzylamino)-1,6-diphenylhex-4-en-3-one


Related News: With nearly 194 billion US dollars of original research medicines facing the expiration of patents in the past five years, more and more domestic companies are focusing on the corresponding characteristic APIs, and have started research and development and production preparations in advance. The scale of production and export of APIs will continue to expand and grow.2-Cyclopropyl-4-(4-fluorophenyl)quinoline-3-carbaldehyde The first is the API – which is the central ingredient.314771-88-5 Exceeding impurities in the drug substance may cause the product and its preparation to be recalled. The company receives an FDA warning letter or a CEP certificate suspension, which in turn will cause customer compensation, product recall costs, and asset impairment losses to affect the company’s performance.168683-02-1 Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.Biogen last month revived its plans to seek U.S. approval for its aducanumab treatment after announcing in March that it would terminate two large clinical trials for the drug. But some analysts believed FDA approval is highly unlikely.

Related Products
Product Name
1-Chlorooctane View Details
4-Iodo-2-(trifluoromethyl)benzonitrile View Details
3-Fluoro-2-methylbenzonitrile View Details
Tert-Butyl Glycinate manufacturer Acetyl Hexapeptide-30 manufacturer Furfuryl thiopropionate manufacturer 4-Bromo-2,3-difluorophenol manufacturer dAMP manufacturer